https://www.socictopen.socict.org/files/original/21aaac0fed60737fa8d1611c1fc93fc3.pdf ee19e07beece970ecfc3bf14b2283fc6 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource AN EARLY ASSESSMENT OF THE EFFICACY OF MEDICINES IN THE TREATMENT OF PATIENTS WITH COVID - 19 Creator An entity primarily responsible for making the resource A. S. Kolbin Description An account of the resource Coronavirus disease-2019 is considered the very recent challenge to world community. While still lacking specific vaccines, the healthcare system is in urgent need for effective and safe medical drugs. We have evaluated the medical technologies for COVID-19 which are under study now. The search was conducted on СlinicalTrials.gov until the start of April 2020. Hence, it was shown that the worldwide rise in new clinical trials concerning COVID-19 is increasing by 65% per week. The interventional Phase II and III clinical trials are more often performed. Most studies are scheduled or conducted in Western Europe (n = 92), China (n = 79), and the United States (n = 51). Surrogate outcome points are usually evaluated, such as clinical recovery, recovery based on clinical scores of symptoms (fever, cough, diarrhea, myalgia, shortness of breath), lack of dyspnea progression, rate of artificial ventilation, rates of admission to the ICU, etc. Antimalarial drugs that are mostly studied. At the present time, it is not possible to discuss efficacy and safety of any drug in the COVID-19 treatment, since most studies are launched quiet recently. The therapeutic regimens proposed now in clinical recommendations are not evidence-based, and appropriate studies are, at best, still considered hypothetic. Date A point or period of time associated with an event in the lifecycle of the resource 2019 Subject The topic of the resource chloroquine, Clinical trials, Monoclonal Antibodies, hydroxychloroquine, Lopinavir/ritonavir, Coronavirus infection, remdesivir, COVID-19 Identifier An unambiguous reference to the resource within a given context DOI: 10.15789/2220-7619-AEA-1458 Source A related resource from which the described resource is derived Infekciâ i Immunitet Publisher An entity responsible for making the resource available Sankt-Peterburg : NIIÈM imeni Pastera Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Infectious and parasitic diseases